PL371774A1 - Neuroprotective treatment methods using selective inos inhibitors - Google Patents

Neuroprotective treatment methods using selective inos inhibitors

Info

Publication number
PL371774A1
PL371774A1 PL02371774A PL37177402A PL371774A1 PL 371774 A1 PL371774 A1 PL 371774A1 PL 02371774 A PL02371774 A PL 02371774A PL 37177402 A PL37177402 A PL 37177402A PL 371774 A1 PL371774 A1 PL 371774A1
Authority
PL
Poland
Prior art keywords
treatment methods
inos inhibitors
neuroprotective treatment
selective inos
selective
Prior art date
Application number
PL02371774A
Other languages
English (en)
Polish (pl)
Inventor
Pamela T. Manning
Jane R. Connor
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of PL371774A1 publication Critical patent/PL371774A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL02371774A 2001-09-24 2002-09-24 Neuroprotective treatment methods using selective inos inhibitors PL371774A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/961,521 US20030119826A1 (en) 2001-09-24 2001-09-24 Neuroprotective treatment methods using selective iNOS inhibitors

Publications (1)

Publication Number Publication Date
PL371774A1 true PL371774A1 (en) 2005-06-27

Family

ID=25504581

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02371774A PL371774A1 (en) 2001-09-24 2002-09-24 Neuroprotective treatment methods using selective inos inhibitors

Country Status (13)

Country Link
US (1) US20030119826A1 (enExample)
EP (1) EP1429752A1 (enExample)
JP (1) JP2005508910A (enExample)
KR (1) KR20040039394A (enExample)
CN (1) CN1556698A (enExample)
AU (1) AU2002327042A2 (enExample)
BR (1) BR0212989A (enExample)
CA (1) CA2455989A1 (enExample)
IL (1) IL161005A0 (enExample)
MX (1) MXPA04002710A (enExample)
PL (1) PL371774A1 (enExample)
WO (1) WO2003026638A1 (enExample)
ZA (1) ZA200402288B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SG10201508623RA (en) * 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
MX2011002033A (es) * 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
CA2771203C (en) * 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE295832T1 (de) * 2000-03-24 2005-06-15 Pharmacia Corp Amidino-verbindung sowie salze davon verwendbar als hemmstoffe der stickstoffmonoxid-synthase
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Also Published As

Publication number Publication date
AU2002327042A2 (en) 2003-04-07
CA2455989A1 (en) 2003-04-03
ZA200402288B (en) 2006-12-27
US20030119826A1 (en) 2003-06-26
KR20040039394A (ko) 2004-05-10
WO2003026638A1 (en) 2003-04-03
MXPA04002710A (es) 2004-07-05
CN1556698A (zh) 2004-12-22
BR0212989A (pt) 2005-04-26
IL161005A0 (en) 2004-08-31
EP1429752A1 (en) 2004-06-23
JP2005508910A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
IL213240A0 (en) Method of treatment using lighnd-immunogen conjugates
GB0115980D0 (en) Apparatus and methods
SG93299A1 (en) Garbage treatment apparatus
GB0129976D0 (en) Treatment method
GB0118383D0 (en) Therapeutic methods
IL161005A0 (en) Neuroprotective treatment methods using selective inos inhibitors
EP1535577A4 (en) LIGA TION TREATMENT UNIT
GB0120147D0 (en) Treatment method
GB0319239D0 (en) Process and apparatus
GB0124124D0 (en) Methods of treatment
SG89379A1 (en) Treatment apparatus
GB0130763D0 (en) Treatment methods
GB0026838D0 (en) Treatment method
GB0008921D0 (en) Method of treatment
IL161004A0 (en) Ophthalmologic treatment methods using selective inos inhibitors
HK1068248A (en) Neuroprotective treatment methods using selective inos inhibitors
GB0031321D0 (en) Treatment
EP1303281A4 (en) METHODS OF TREATMENT
GB0104555D0 (en) New Therapeutic method
GB0126253D0 (en) Treatment method
GB0130694D0 (en) Treatment
GB0102927D0 (en) Treatment method
GB0109519D0 (en) Nimico treatment
GB0116837D0 (en) Treatment
SI1377249T1 (sl) Priprava za akupunkturno terapijo

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)